The red flag signs of bladder and prostate cancer you need to know as F1 legend Eddie Jordan dies
ABOUT 55,000 new prostate cancer cases are recorded every year in the UK. Bladder cancer is less common, with around 10,500 ...
The American Journal of Managed Care1d
FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer
The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer (MIBC).
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...
Healio7d
Urine test may aid detection of high-grade invasive bladder cancer
A urinary DNA methylation test showed potential for detecting high-grade or invasive bladder cancer, according to results of ...
CURE4d
FDA Approves Imfinzi Therapy in Muscle Invasive Bladder Cancer
The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...
Fierce Pharma1d
AstraZeneca bulks up Imfinzi's prowess with FDA nod in bladder cancer around surgery
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
Renal & Urology News7d
Discrepancy Common Between Clinical, Pathologic Stage After Radical Cystectomy
Discrepancies between clinical and pathologic staging of muscle-invasive bladder cancer (MIBC) are found in three-quarters of ...
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...
Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress
Aura Biosciences (AURA) has reported its Q4 and full-year 2024 financial results, prompting an ongoing decline in shares ...